Golden State Equity Partners’s Edwards Lifesciences EW Stock Holding History

Golden State Equity Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.2K	Buy	+190	New	+$15.7K	﹤0.01%	1179

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Golden State Equity Partners's EW Position: Q1 2026 in Review

Golden State Equity Partners opened a new position in Edwards Lifesciences (EW) in Q1 2026: 190 shares worth $15.2K. The stake represents ﹤0.01% of the portfolio and ranks #1179 among its holdings.

1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Golden State Equity Partners held 190 shares of Edwards Lifesciences worth $15.2K as of Q1 2026.
Edwards Lifesciences was a new Golden State Equity Partners position in Q1 2026.
Edwards Lifesciences made up ﹤0.01% of Golden State Equity Partners's portfolio in Q1 2026, its #1179 holding.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.